Natco Pharma Gets One USFDA Observation For Hyderabad API unit

Natco Pharma Ltd. on Friday said the US Food and Drug Administration issued a Form 483 with one observation for its active pharmaceutical ingredients facility at Mekaguda in Hyderabad. The inspection was carried out from Monday to Friday, the company said in a press release.

The company said the observation was procedural in nature and added that it is confident of addressing the issue comprehensively.